Connect with the future of healthcare
Founded in Switzerland by surgeons in 2020, Spirecut developed an ultra-minimally invasive technique with single-use instruments to simplify and enhance the safety of common surgeries. We use a tiny pinhole instead of a traditional incision, which helps patients recover faster and reduces the risk of complications. With CE marking and FDA-listing, our products entered the market in early 2024.
In the market
15.661.989€
2026
Medical devices
5%
1.000€
Share this project on your website.
Copy and paste the following code into your content.
Spirecut SA is a Swiss medical device company founded in April 2020 with CHF 100,000 (€106,383) in capital, developing patented instruments for percutaneous treatment of carpal tunnel syndrome and trigger finger. Our long-term vision is to lead in percutaneous surgery across various indications and anatomical locations.
SPIRE is the acronym for Swiss Percutaneous Instruments, allowing Rapid and Efficient surgery. SPIRE evokes also the similarity of the conical shape of the cutting extremity of the instruments. CUT refers to the fact that that the instruments allow quick and efficient release of the pathological tissues.
The founder, Pr F. Schuind, an orthopaedic hand/upper extremity surgeon with double citizenship, Swiss and Belgian, was until September 2020 head of the department of Orthopaedics and Traumatology of Erasme University Hospital (Brussels). He now spends the majority of his time in Switzerland, while keeping a limited consultancy activity in Brussels, which allows him to keep close contacts with clinicians and patients. He is a member of many scientific societies and has outstanding scientific curriculum.
In 2018, a collaborator of Pr Schuind in Brussels, Pr F. Moungondo, also an orthopaedic surgeon, pioneered an ultrasound-guided technique using modified catheters for hand surgeries. Based on this experience, Pr Schuind offered Pr Moungondo to develop and to patent an original medical device, under a royalty contract. This first patent, owned by Spirecut, has now been granted in Europe, China/Hong Kong, Australia and in Japan and is pending in USA and Canada. Two additional patents have been filed, one in 2021 (entering just now national phases) and another recently for a companion product, the Sono-Bath device.
Investing in Spirecut is an excellent opportunity to support an alternative treatment for very common muscular conditions that today are only addressed through surgery. Spirecut has developed incision-free surgical instruments that increase precision and significantly shorten both surgery time, which takes less than 10 minutes, and recovery time.
With three patents and FDA, CE, and ISO certifications, Spirecut is already selling in countries like Switzerland, Ireland, the UK, the U.S., and Canada. They are currently seeking funding to expand their global presence and continue developing new products. Capital Cell sees in this company an investment opportunity with strong growth potential and a clear impact on improving surgical treatments.
Although Spirecut offers a promising solution, adoption by healthcare professionals could be slower than expected. Physicians accustomed to traditional surgical techniques may be hesitant to switch to a new technology, especially if they don't see an immediate benefit or if the learning curve is significant. Additionally, while Spirecut's instruments provide clear advantages, they could face price competition from more affordable surgical solutions.
Already have an account? Please login here .
